Scientists test gene fix and drug combo for rare immune diseases in the lab
NCT ID NCT07261891
First seen Dec 15, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study uses blood samples from 20 adults with primary immunodeficiency diseases to see how JAK inhibitors affect the immune system and whether a gene therapy approach can correct genetic faults. The goal is to gather knowledge that could lead to better treatments. Participants provide blood for lab experiments only; no treatment is given.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Leuven,
RECRUITINGLeuven, Vlaams-Brabant, 3000, Belgium
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.